InvestSMART

EMvision Medical Devices Limited (ASX:EMV)

ALERT: Price-sensitive ASX Announcement for EMV
Current share price for EMV : $1.620 0.04 (2.53%)+
Announcement
Release
16 Mar 2026 8:16AM
Price at Release
$1.580
Full Release
download
Summary
EMVision Medical Devices Limited announced the receipt of a $3.8 million R&D tax refund for eligible research and development activities conducted in the financial year ending 30 June 2025. Additionally, the company has received approval from AusIndustry for its Advance Overseas Finding application, allowing tax rebates on overseas expenditures related to the emu™ pivotal trial and market access activities. These developments enhance EMVision's financial position and support ongoing clinical and market initiatives.
Key Points
  • $3.8 million R&D tax refund received for eligible activities in the financial year ended 30 June 2025.
  • Advance Overseas Finding approved by AusIndustry for overseas expenditures on the emu™ pivotal trial.
  • Eligible overseas expenses include US-based CRO and hospital site costs, administration, professional advisory, and regulatory expenses.
  • Access to Australia's 43.5% R&D tax rebate for overseas expenditures for financial years 2025, 2026, and 2027.
  • Strengthened funding position supports emu™ pivotal trial and market access initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.